You are here

  • Home
  • Archive
  • Volume 68, Issue 5
  • The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease

Article info

Article menu
Download PDFPDF
Paper
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease

Authors

  1. Dr Paola Piccini, MRC Cyclotron Unit, Hammersmith Hospital, Du Cane Road, W12 0NN London, UKpaola.piccini{at}csc.mrc.ac.uk
View Full Text

Citation

Piccini P, Brooks DJ, Korpela K, et al
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease
Journal of Neurology, Neurosurgery & Psychiatry 2000;68:589-594.

Publication history

  • Received March 12, 1999
  • Revised November 10, 1999
  • Accepted November 26, 1999
  • First published May 1, 2000.
Online issue publication 
April 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Journal of Neurology, Neurosurgery, and Psychiatry